Scholarlink

Background <p>Fibroblast activation protein inhibitor (FAPI) is a novel PET tracer that targets various malignant tumors. Although some studies have demonstrated that <sup>68</sup>Ga-labeled FAPI PET provides diagnostic images shortly after injection, reports on early-phase imaging using [<sup>18</sup>F]FAPI-74 are limited. This study evaluated the diagnostic potential of early-phase [<sup>18</sup>F]FAPI-74 PET/CT imaging.</p> Methods <p>The cohort comprised 32 patients who underwent whole-body [<sup>18</sup>F]FAPI-74 PET/CT at three time points: 10, 30, and 60&#xa0;min after administration. The uptake of [<sup>18</sup>F]FAPI-74 in normal organs and tumors at each time point was evaluated and compared using standardized uptake value (SUV). The contrast between tumor and background uptake was assessed using tumor-to-blood ratios (TBRs), calculated as the ratio of tumor SUVmax to blood pool SUVmean.</p> Results <p>The uptake of [<sup>18</sup>F]FAPI-74 in most organs gradually decreased, except in the mammary gland and nipple. Moreover, uptake due to the excretion increased over time in the gallbladder, and bile duct. Among the 72 lesions identified across patients, the median SUVmax of the tumors remained relatively stable across the time points (5.00, 5.16, and 5.11 at 10, 30, and 60&#xa0;min, respectively), while the median TBRs gradually increased (1.57, 2.24, and 2.94, respectively). Subgroup analysis revealed a similar pattern of increasing median TBRs in primary tumors (2.76, 3.72, and 4.04, respectively), lymph node metastases and peritoneal dissemination (1.67, 2.47, and 3.58, respectively), and lung metastases (0.99, 1.35, and 1.48, respectively).</p> Conclusions <p>TBRs were highest at 60&#xa0;min after administration. However, early-phase imaging was considered useful because of its sufficient diagnostic contrast and low physiological uptake in the biliary system.</p> Trial registration <p>UMIN Clinical Trials Registry, UMIN000051687. Registered 22 July 2023,&#xa0;<a href="https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_his_list.cgi?recptno=R000058594">https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_his_list.cgi?recptno=R000058594</a>.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Optimizing [18F]FAPI-74 PET/CT imaging: insights from Early-phase tumor uptake and tissue contrast

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年12月4日

查看全文
  • Yuki Hoda,
  • Keiji Shimizu,
  • Hiroyuki Nishida,
  • Yasuhiko Ikari,
  • Go Akamatsu,
  • Keiichi Matsumoto,
  • Michio Senda,
  • Tomohiko Yamane

摘要

Background

Fibroblast activation protein inhibitor (FAPI) is a novel PET tracer that targets various malignant tumors. Although some studies have demonstrated that 68Ga-labeled FAPI PET provides diagnostic images shortly after injection, reports on early-phase imaging using [18F]FAPI-74 are limited. This study evaluated the diagnostic potential of early-phase [18F]FAPI-74 PET/CT imaging.

Methods

The cohort comprised 32 patients who underwent whole-body [18F]FAPI-74 PET/CT at three time points: 10, 30, and 60 min after administration. The uptake of [18F]FAPI-74 in normal organs and tumors at each time point was evaluated and compared using standardized uptake value (SUV). The contrast between tumor and background uptake was assessed using tumor-to-blood ratios (TBRs), calculated as the ratio of tumor SUVmax to blood pool SUVmean.

Results

The uptake of [18F]FAPI-74 in most organs gradually decreased, except in the mammary gland and nipple. Moreover, uptake due to the excretion increased over time in the gallbladder, and bile duct. Among the 72 lesions identified across patients, the median SUVmax of the tumors remained relatively stable across the time points (5.00, 5.16, and 5.11 at 10, 30, and 60 min, respectively), while the median TBRs gradually increased (1.57, 2.24, and 2.94, respectively). Subgroup analysis revealed a similar pattern of increasing median TBRs in primary tumors (2.76, 3.72, and 4.04, respectively), lymph node metastases and peritoneal dissemination (1.67, 2.47, and 3.58, respectively), and lung metastases (0.99, 1.35, and 1.48, respectively).

Conclusions

TBRs were highest at 60 min after administration. However, early-phase imaging was considered useful because of its sufficient diagnostic contrast and low physiological uptake in the biliary system.

Trial registration

UMIN Clinical Trials Registry, UMIN000051687. Registered 22 July 2023, https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_his_list.cgi?recptno=R000058594.